| abstract |
The present invention includes and is active by contacting an active substance, an agent capable of destroying the active substance, and an active substance such as buprenorphine and an agent such as potassium permanganate when the TTS is removed from the skin of the patient. It relates to a transdermal therapeutic system (TTS), preferably in the form of transdermal plaster, which causes the material to be destroyed. |